Android Apple

Sangamo Therapeutics Shares Jump After FDA Discussion on Accelerated Approval Pathway for Fabry Disease Drug

By MarketWatch   |   2 months ago
Sangamo Therapeutics Shares Jump After FDA Discussion on Accelerated Approval Pathway for Fabry Disease Drug

Sangamo Therapeutics' stock surged as FDA interaction paved the way for accelerated approval of ST-920 for Fabry disease. The company anticipates a biologics license application submission in 2025, three years ahead of previous estimates, without the need for additional clinical studies.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.